Age >66 years, n (%) |
963 (41.5) |
251 (90) |
0.001 |
Male, n (%) |
1339 (57.8) |
167 (59.9) |
0.522 |
Hypertension, n (%) |
998 (42.9) |
196 (80.3) |
0.001 |
Diabetes mellitus, n (%) |
423 (18.2) |
84 (30.1) |
0.001 |
Chronic heart disease, n (%) |
487 (20.9) |
150 (53.8) |
0.001 |
Chronic pulmonary disease, n (%) |
541 (23.2) |
89 (31.9) |
0.002 |
Chronic renal failure, n (%) |
201 (8.6) |
97 (34.8) |
0.001 |
Liver disease, n (%) |
156 (6.7) |
17 (6.1) |
0.799 |
Haematological malignancy, n (%) |
136 (5.8) |
32 (11.5) |
0.001 |
Solid neoplasm, n (%) |
306 (13.1) |
65 (23.3) |
0.001 |
Solid organ transplantation, n (%) |
45 (1.9) |
9 (3.2) |
0.177 |
HIV, n (%) |
34 (1.5) |
5 (1.8) |
0.602 |
Pre-admission duration of symptoms, n (%) |
|
|
|
≤3 days of symptoms |
464 (19.9) |
113 (40.5) |
0.001 |
4–6 days of symptoms |
629 (27) |
67 (24) |
0.001 |
>6 days of symptoms |
1235 (53) |
99 (35.5) |
0.001 |
Temperature >37°C (N = 2554), n (%) |
1184 (51.4) |
104 (41.4) |
0.003 |
Respiratory rate >21 bpm at day 1–2 (N = 2128), n (%) |
891 (46.7) |
168 (76.7) |
0.001 |
Oxygen saturation ≤94% (N = 2546), n (%) |
1203 (52.4) |
188 (74.9) |
0.001 |
Creatinine >0.92 mg/dL (N = 2593), n (%) |
1017 (43.9) |
211 (77) |
0.001 |
Lactate dehydrogenase >305 U/L (N = 2524), n (%) |
1096 (48.4) |
171 (66.3) |
0.001 |
Lymphocyte count ≤800 cells/mm3 (N = 2593), n (%) |
1127 (48.6) |
182 (66.4) |
0.001 |
C-reactive protein >7.52 mg/dL (N = 2590), n (%) |
1127 (48.7) |
198 (72.3) |
0.001 |
Remdesivir, n (%) |
419 (18) |
19 (6.8) |
0.001 |
Tocilizumab within 3 days, n (%) |
140 (6) |
18 (6.5) |
0.790 |
Corticosteroids within 3 days, n (%) |
264 (11.3) |
27 (9.7) |
0.481 |
ICU admission, n (%) |
415 (17.8) |
61 (21.9) |
0.101 |
Invasive mechanical ventilation, n (%) |
214 (9.2) |
50 (17.9) |
0.001 |